The challenge of introducing new technologies into established
industries is not a problem unique to the biopharmaceutical industry.
However, it may be critical to the long-term competitiveness of
individual manufacturers and, more importantly, the ability to deliver
therapies to patients. This is especially true for new treatment
modalities including cell and gene therapies. We review several barriers
to technology adoption which have been identified in various public
forums including business, regulatory, technology, and people-driven
concerns. We also summarize suitable enablers addressing one or more of
these barriers along with some suggestions for developing additional
synergies.